

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## **New Horizon Health Limited**

**諾輝健康**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6606)**

### **VOLUNTARY ANNOUNCEMENT**

This announcement is made by New Horizon Health Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the business of the Group.

Reference is made to the announcement of the Company on July 10, 2023 in relation to the positive profit alert of the Company for the six months ended June 30, 2023 (the “**Announcement**”). As disclosed in the Announcement, based on the preliminary review of the Group’s unaudited management accounts for the six months ended June 30, 2023 (without taking into account ex-mainland China sales and profit from partners of our Group), the revenue from sales of ColoClear for the six months ended June 30, 2023 is expected to be within the range of RMB480.9 million to RMB500.9 million, and the revenue-recognized volume of ColoClear in the six months ended June 30, 2023 was approximately 428,700 units.

The Company would like to provide the shareholders and potential investors of the Company with further information in relation to the revenue from sales of ColoClear and the revenue-recognized volume of ColoClear, each for the six months ended June 30, 2023.

Below is a table which demonstrates the distribution of the revenue from sales of ColoClear and the revenue-recognized volume of ColoClear via hospital channel, each for the six months ended June 30, 2023:

	<b>Revenue from sales of ColoClear for the six months ended June 30, 2023<sup>(1)</sup></b>	<b>Revenue-recognized volumes of ColoClear in the six months ended June 30, 2023</b>
	<i>RMB million (Unaudited)</i>	<i>(Units)</i>
Class III Hospitals	12.2	9,600
Class II Hospitals	2.3	1,700
Clinics	127.7	79,500
Private Hospitals	80.7	54,200
Others	32.1	27,000
<b>Total</b>	<b>255.0</b>	<b>172,000</b>

Note:

(1) Revenue are calculated with values at the mid-point of the forecast range.

Below is a table which demonstrates various key data in respect of the revenue-recognized volume of ColoClear in the six months ended June 30, 2023 from hospital channel:

Total revenue-recognized volume of ColoClear in the six months ended June 30, 2023 from hospital channels:	<b>172,000 units</b>
------------------------------------------------------------------------------------------------------------	----------------------

Top five provinces:	<b>Zhejiang Province, Shanghai, Beijing, Shandong Province, Guangdong Province</b>
---------------------	------------------------------------------------------------------------------------

Median age:	<b>47</b>
-------------	-----------

Male to Female Ratio:	<b>Approximately 55% are male and 45% are female</b>
-----------------------	------------------------------------------------------

**Shareholders of the Company and potential investors are advised not to place any reliance on the information disclosed herein but to exercise due caution when dealing in the securities of the Company. When in doubt, shareholders of the Company and potential investors are advised to seek professional advice from professional or financial advisers.**

By order of the Board  
**New Horizon Health Limited**  
**Mr. YeQing ZHU**  
*Chairman*

Hong Kong, July 12, 2023

*As at the date of this announcement, the Board comprises Mr. YeQing ZHU as Chairman and executive Director, Dr. Yiyou CHEN as executive Director, Mr. Naxin YAO as non-executive Director, and Mr. Danke YU, Prof. Hong WU and Dr. Donald Kwok Tung LI as independent non-executive Directors.*